高级检索
当前位置: 首页 > 详情页

Correlation of Hyaluronic Acid (HA), Syndecan-1 (SDC-1), Heparan Sulfate (HS) with early stage ad organ dysfunction in sepsis patients

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Critical Care Medicine,The First People's Hospital of Yunnan Province,Affiliated Hospital of Kunming University of Science and Technology,Kunming,650032,China. [2]Kunming Medical University Affiliated Yan'an Hospital Intensive Care Unit, Kunming City, Yunnan Province, China. 650051.
出处:
ISSN:

关键词: hyaluronic acid polyligand proteoglycan-1 sulfated heparin glycocalyx sepsis

摘要:
This study aimed to explore the relationship between the changes in early degradation products of polysaccharide coatings (such as hyaluronic acid (HA), syndecan-1 (SDC-1), and heparan sulfate (HS)) and the development of organ dysfunction in sepsis patients. We conducted a retrospective analysis on 140 sepsis patients admitted from January 2021 to June 2022, who formed the study group; 100 healthy individuals who underwent health checks during the same period were included as the control group. The study found that the expression levels of HA, SDC-1, and HS upon admission and within 24 hours of admission in sepsis patients, as well as the early change rates, were positively correlated with organ dysfunction (P < 0.05). Through receiver operating characteristic (ROC) curve analysis, we discovered that the early change rates of HA, SDC-1, and HS have high predictive value for organ dysfunction in sepsis patients, with the combined predictive value being the most significant. The study conclusion points out that the increased levels of HA, SDC-1, HS, and other degradation products of polysaccharide coatings in the early stage of sepsis are positively associated with the occurrence of organ dysfunction. Clinicians can utilize the early expression changes of these biomarkers to predict the risk of organ dysfunction in sepsis patients, enabling timely implementation of preventive measures that may improve patient outcomes.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 药学
JCR分区:
出版当年[2024]版:
最新[2023]版:
Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Q2 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Department of Critical Care Medicine,The First People's Hospital of Yunnan Province,Affiliated Hospital of Kunming University of Science and Technology,Kunming,650032,China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:89078 今日访问量:0 总访问量:752 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号 ICP备案:滇ICP备15003244号